MAP2K1 and central nervous system cancer: From all the identified treatments, we focused on trametinib based on the efficacy of MEK1/2 inhibition in RMS preclinical studies [71], and prior promising clinical studies in pediatric glioma patients with active MAPK signaling [58, 59].